VIBATIV®: Theravance Biopharma reports new preliminary data from the ongoing TOUR study
by Press Release from Outbreak News Today on (#2M4YB)
Theravance Biopharma, Inc. today announced that new preliminary data from the ongoing Telavancin Observational Use Registry (TOURa) study are the focus of three poster presentations at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). TOUR, which has enrolled its target of 1,000 patients, is designed to report how VIBATIV(R) (telavancin) is being ["]
The post VIBATIV(R): Theravance Biopharma reports new preliminary data from the ongoing TOUR study appeared first on Outbreak News Today.